

Patient		Physician	
Name : xxxxxxxxxxxx		Name : xx xxxxxxxxxxxx	
Gender : M	Date of Birth : DD/MM/YYYY	Institute : xxxxxxxxxxxx	
Diagnosis : NSCLC			
Sample Type : Plasma	Sample Collection Date : DD/MM/YYYY	Sample ID :PB_CG_SG_XXXX-XX_XX	
Test : PositiveSelect Lung	Technology : Illumina NGS	Coverage : 1000x	Report Date : DD/MM/YYYY

Patient Tumor Type Specific Genes

Gene	Genetic Alteration	Result
ALK-EML4 Rearrangements	No alteration detected	Negative
BRAF Mutation [p.V600E]	No alteration detected	Negative
EGFR Mutation Exon 18, 19, 20, 21	No alteration detected	Negative
ERBB2 Mutation [HER2] [Exon 20 insertion]	No alteration detected	Negative
ERBB2 Amplification [HER2]	No alteration detected	Negative
KRAS Mutation [Codon 12]	No alteration detected	Negative
MET Amplification	No alteration detected	Negative
MET mutation [Exon 14 skipping]	No alteration detected	Negative
RET Rearrangements	No alteration detected	Negative
ROS1 Rearrangements	No alteration detected	Negative

Note: Genomic alterations in the 8 genes related to cancer type (Lung Cancer) as listed in NCCN guidelines are reported here.

About PositiveSelect Lung

PositiveSelect Lung is a targeted-NGS based diagnostic test, which tests for all four categories of genomic alterations; single nucleotide variations, indels, copy number variations, structural variations, in the 8 genes as listed above. It adds the advantage of making available a comprehensive molecular testing solution as indicated in the guidelines with specificity and sensitivity higher than the conventional platforms.

The PositiveSelect Lung test, has been designed to work both on FFPE and liquid biopsy, thus ensuring the criteria for sample procurement and requirement is made convenient. The blood collection tube that comes with the test, ensures low risk of sample degradation and extraction of adequate ctDNA for the test. The custom-designed assay enriches all the 8 recommended gene targets from the cfDNA and further is sequenced in a depth of 1000X on the Next-Seq Illumina NGS platform. The end result involves massive parallel sequencing of all the enriched cancer-specific target regions along with flanking introns.

Analyzed by:

Verified by:

Scientific Officer

Sr. Scientific Officer

Disclaimer: The information in this report is meant for medical professionals only. This report should not be construed as personal medical advice and is not intended to replace medical advice ordered by physicians. This document should not be used to establish any standard of care. Clinicians should use their own clinical judgment and not base clinical decisions solely on this document. Positive Bioscience will not be liable for any direct, indirect, consequential, special, exemplary, or other damages. Using this report means the person undertaking this test consents and fully agrees to all terms listed at <http://www.positivebioscience.com/terms.aspx>

Positive Biosciences Ltd.

Registered Office: 645, Anna Salai, Thousand Lights, Chennai - 600 006. Tel.: 044-28290187

Corporate Office: 1st Floor, Kohinoor City Mall, Gate No. 1, Opp. Don Bosco School, Premier Road, Kiroi Road, Kurla (West), Mumbai - 400 070.
Toll Free: 1800 1235 835 Website: www.positivebioscience.com Email: info@positivebioscience.com CIN: U93000TN1995PLC030290